EGFR Antibody | Affinity Biosciences

製品:	EGFR Antibody
カタログ:	AF6043
タンパク質の説明:	Rabbit polyclonal antibody to EGFR
アプリケーション:	WB IHC IF/ICC
Cited expt.:	WB, IHC, IF/ICC
反応性:	Human, Mouse, Rat
予測:	Pig, Bovine, Sheep, Rabbit
分子量:	134kDa; 134kD(Calculated).
ユニプロット:	P00533
RRID:	AB_2834971

類似製品を見る>>

サイズ	価格	在庫状況
100ul	$280	在庫あり
200ul	$350	在庫あり

プロトコル

製品説明

ソース:

Rabbit

アプリケーション:

WB 1:500-1:2000, IHC 1:50-1:200, IF/ICC 1:100-1:500
*The optimal dilutions should be determined by the end user. For optimal experimental results, antibody reuse is not recommended.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

反応性:

Human,Mouse,Rat

予測:

Pig(92%), Bovine(92%), Sheep(92%), Rabbit(92%)

クローナリティ:

Polyclonal

特異性:

EGFR Antibody detects endogenous levels of total EGFR.

RRID:

AB_2834971
引用形式: Affinity Biosciences Cat# AF6043, RRID:AB_2834971.

コンジュゲート:

Unconjugated.

精製:

The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).

保存:

Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.

別名:

折りたたみ／展開

Avian erythroblastic leukemia viral (v erb b) oncogene homolog; Cell growth inhibiting protein 40; Cell proliferation inducing protein 61; EGF R; EGFR; EGFR_HUMAN; Epidermal growth factor receptor (avian erythroblastic leukemia viral (v erb b) oncogene homolog); Epidermal growth factor receptor (erythroblastic leukemia viral (v erb b) oncogene homolog avian); Epidermal growth factor receptor; erb-b2 receptor tyrosine kinase 1; ERBB; ERBB1; Errp; HER1; mENA; NISBD2; Oncogen ERBB; PIG61; Proto-oncogene c-ErbB-1; Receptor tyrosine protein kinase ErbB 1; Receptor tyrosine-protein kinase ErbB-1; SA7; Species antigen 7; Urogastrone; v-erb-b Avian erythroblastic leukemia viral oncogen homolog; wa2; Wa5;

免疫原

免疫原:

A synthesized peptide derived from human EGFR, corresponding to a region within C-terminal amino acids.

Uniprot:

P00533(EGFR_HUMAN) >>Visit HPA database.

遺伝子(ID):

EGFR(1956)

発現特異性:

P00533 EGFR_HUMAN:

Ubiquitously expressed. Isoform 2 is also expressed in ovarian cancers.

タンパク質の説明:

EGFR is a receptor tyrosine kinase. Receptor for epidermal growth factor (EGF) and related growth factors including TGF-alpha, amphiregulin, betacellulin, heparin-binding EGF-like growth factor, GP30 and vaccinia virus growth factor. Is involved in the control of cell growth and differentiation.

タンパク質配列:

P00533 EGFR_HUMAN:
Protein BLAST With
NCBI/
ExPASy/
Uniprot

MRPSGTAGAALLALLAALCPASRALEEKKVCQGTSNKLTQLGTFEDHFLSLQRMFNNCEVVLGNLEITYVQRNYDLSFLKTIQEVAGYVLIALNTVERIPLENLQIIRGNMYYENSYALAVLSNYDANKTGLKELPMRNLQEILHGAVRFSNNPALCNVESIQWRDIVSSDFLSNMSMDFQNHLGSCQKCDPSCPNGSCWGAGEENCQKLTKIICAQQCSGRCRGKSPSDCCHNQCAAGCTGPRESDCLVCRKFRDEATCKDTCPPLMLYNPTTYQMDVNPEGKYSFGATCVKKCPRNYVVTDHGSCVRACGADSYEMEEDGVRKCKKCEGPCRKVCNGIGIGEFKDSLSINATNIKHFKNCTSISGDLHILPVAFRGDSFTHTPPLDPQELDILKTVKEITGFLLIQAWPENRTDLHAFENLEIIRGRTKQHGQFSLAVVSLNITSLGLRSLKEISDGDVIISGNKNLCYANTINWKKLFGTSGQKTKIISNRGENSCKATGQVCHALCSPEGCWGPEPRDCVSCRNVSRGRECVDKCNLLEGEPREFVENSECIQCHPECLPQAMNITCTGRGPDNCIQCAHYIDGPHCVKTCPAGVMGENNTLVWKYADAGHVCHLCHPNCTYGCTGPGLEGCPTNGPKIPSIATGMVGALLLLLVVALGIGLFMRRRHIVRKRTLRRLLQERELVEPLTPSGEAPNQALLRILKETEFKKIKVLGSGAFGTVYKGLWIPEGEKVKIPVAIKELREATSPKANKEILDEAYVMASVDNPHVCRLLGICLTSTVQLITQLMPFGCLLDYVREHKDNIGSQYLLNWCVQIAKGMNYLEDRRLVHRDLAARNVLVKTPQHVKITDFGLAKLLGAEEKEYHAEGGKVPIKWMALESILHRIYTHQSDVWSYGVTVWELMTFGSKPYDGIPASEISSILEKGERLPQPPICTIDVYMIMVKCWMIDADSRPKFRELIIEFSKMARDPQRYLVIQGDERMHLPSPTDSNFYRALMDEEDMDDVVDADEYLIPQQGFFSSPSTSRTPLLSSLSATSNNSTVACIDRNGLQSCPIKEDSFLQRYSSDPTGALTEDSIDDTFLPVPEYINQSVPKRPAGSVQNPVYHNQPLNPAPSRDPHYQDPHSTAVGNPEYLNTVQPTCVNSTFDSPAHWAQKGSHQISLDNPDYQQDFFPKEAKPNGIFKGSTAENAEYLRVAPQSSEFIGA

種類予測

種類予測:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species

Results

Score

Pig

Bovine

Sheep

Rabbit

Xenopus

Horse

Dog

Zebrafish

Chicken

Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

研究背景

P00533_EGFR_HUMAN

機能:

Receptor tyrosine kinase binding ligands of the EGF family and activating several signaling cascades to convert extracellular cues into appropriate cellular responses. Known ligands include EGF, TGFA/TGF-alpha, AREG, epigen/EPGN, BTC/betacellulin, epiregulin/EREG and HBEGF/heparin-binding EGF. Ligand binding triggers receptor homo- and/or heterodimerization and autophosphorylation on key cytoplasmic residues. The phosphorylated receptor recruits adapter proteins like GRB2 which in turn activates complex downstream signaling cascades. Activates at least 4 major downstream signaling cascades including the RAS-RAF-MEK-ERK, PI3 kinase-AKT, PLCgamma-PKC and STATs modules. May also activate the NF-kappa-B signaling cascade. Also directly phosphorylates other proteins like RGS16, activating its GTPase activity and probably coupling the EGF receptor signaling to the G protein-coupled receptor signaling. Also phosphorylates MUC1 and increases its interaction with SRC and CTNNB1/beta-catenin. Positively regulates cell migration via interaction with CCDC88A/GIV which retains EGFR at the cell membrane following ligand stimulation, promoting EGFR signaling which triggers cell migration. Plays a role in enhancing learning and memory performance (By similarity).

Isoform 2 may act as an antagonist of EGF action.

(Microbial infection) Acts as a receptor for hepatitis C virus (HCV) in hepatocytes and facilitates its cell entry. Mediates HCV entry by promoting the formation of the CD81-CLDN1 receptor complexes that are essential for HCV entry and by enhancing membrane fusion of cells expressing HCV envelope glycoproteins.

PTMs:

Phosphorylated on Tyr residues in response to EGF. Phosphorylation at Ser-695 is partial and occurs only if Thr-693 is phosphorylated. Phosphorylation at Thr-678 and Thr-693 by PRKD1 inhibits EGF-induced MAPK8/JNK1 activation. Dephosphorylation by PTPRJ prevents endocytosis and stabilizes the receptor at the plasma membrane. Autophosphorylation at Tyr-1197 is stimulated by methylation at Arg-1199 and enhances interaction with PTPN6. Autophosphorylation at Tyr-1092 and/or Tyr-1110 recruits STAT3. Dephosphorylated by PTPN1 and PTPN2.

Monoubiquitinated and polyubiquitinated upon EGF stimulation; which does not affect tyrosine kinase activity or signaling capacity but may play a role in lysosomal targeting. Polyubiquitin linkage is mainly through 'Lys-63', but linkage through 'Lys-48', 'Lys-11' and 'Lys-29' also occurs. Deubiquitination by OTUD7B prevents degradation. Ubiquitinated by RNF115 and RNF126 (By similarity).

Palmitoylated on Cys residues by ZDHHC20. Palmitoylation inhibits internalization after ligand binding, and increases the persistence of tyrosine-phosphorylated EGFR at the cell membrane. Palmitoylation increases the amplitude and duration of EGFR signaling.

Methylated. Methylation at Arg-1199 by PRMT5 stimulates phosphorylation at Tyr-1197.

細胞の位置付け:

Cell membrane>Single-pass type I membrane protein. Endoplasmic reticulum membrane>Single-pass type I membrane protein. Golgi apparatus membrane>Single-pass type I membrane protein. Nucleus membrane>Single-pass type I membrane protein. Endosome. Endosome membrane. Nucleus.
Note: In response to EGF, translocated from the cell membrane to the nucleus via Golgi and ER (PubMed:20674546). Endocytosed upon activation by ligand (PubMed:2790960, PubMed:17182860, PubMed:27153536). Colocalized with GPER1 in the nucleus of estrogen agonist-induced cancer-associated fibroblasts (CAF) (PubMed:20551055).

Secreted.

組織特異性:

Ubiquitously expressed. Isoform 2 is also expressed in ovarian cancers.

タンパク質ファミリー:

Belongs to the protein kinase superfamily. Tyr protein kinase family. EGF receptor subfamily.

研究領域

· Cellular Processes > Transport and catabolism > Endocytosis. (View pathway)

· Cellular Processes > Cellular community - eukaryotes > Focal adhesion. (View pathway)

· Cellular Processes > Cellular community - eukaryotes > Adherens junction. (View pathway)

· Cellular Processes > Cellular community - eukaryotes > Gap junction. (View pathway)

· Cellular Processes > Cell motility > Regulation of actin cytoskeleton. (View pathway)

· Environmental Information Processing > Signal transduction > MAPK signaling pathway. (View pathway)

· Environmental Information Processing > Signal transduction > ErbB signaling pathway. (View pathway)

· Environmental Information Processing > Signal transduction > Ras signaling pathway. (View pathway)

· Environmental Information Processing > Signal transduction > Rap1 signaling pathway. (View pathway)

· Environmental Information Processing > Signal transduction > Calcium signaling pathway. (View pathway)

· Environmental Information Processing > Signaling molecules and interaction > Cytokine-cytokine receptor interaction. (View pathway)

· Environmental Information Processing > Signal transduction > HIF-1 signaling pathway. (View pathway)

· Environmental Information Processing > Signal transduction > FoxO signaling pathway. (View pathway)

· Environmental Information Processing > Signal transduction > Phospholipase D signaling pathway. (View pathway)

· Environmental Information Processing > Signal transduction > PI3K-Akt signaling pathway. (View pathway)

· Environmental Information Processing > Signal transduction > Jak-STAT signaling pathway. (View pathway)

· Human Diseases > Drug resistance: Antineoplastic > EGFR tyrosine kinase inhibitor resistance.

· Human Diseases > Drug resistance: Antineoplastic > Endocrine resistance.

· Human Diseases > Infectious diseases: Bacterial > Epithelial cell signaling in Helicobacter pylori infection.

· Human Diseases > Infectious diseases: Viral > Hepatitis C.

· Human Diseases > Infectious diseases: Viral > Human papillomavirus infection.

· Human Diseases > Cancers: Overview > Pathways in cancer. (View pathway)

· Human Diseases > Cancers: Overview > Proteoglycans in cancer.

· Human Diseases > Cancers: Overview > MicroRNAs in cancer.

· Human Diseases > Cancers: Specific types > Colorectal cancer. (View pathway)

· Human Diseases > Cancers: Specific types > Pancreatic cancer. (View pathway)

· Human Diseases > Cancers: Specific types > Endometrial cancer. (View pathway)

· Human Diseases > Cancers: Specific types > Glioma. (View pathway)

· Human Diseases > Cancers: Specific types > Prostate cancer. (View pathway)

· Human Diseases > Cancers: Specific types > Melanoma. (View pathway)

· Human Diseases > Cancers: Specific types > Bladder cancer. (View pathway)

· Human Diseases > Cancers: Specific types > Non-small cell lung cancer. (View pathway)

· Human Diseases > Cancers: Specific types > Breast cancer. (View pathway)

· Human Diseases > Cancers: Specific types > Hepatocellular carcinoma. (View pathway)

· Human Diseases > Cancers: Specific types > Gastric cancer. (View pathway)

· Human Diseases > Cancers: Overview > Central carbon metabolism in cancer. (View pathway)

· Human Diseases > Cancers: Overview > Choline metabolism in cancer. (View pathway)

· Organismal Systems > Endocrine system > Estrogen signaling pathway. (View pathway)

· Organismal Systems > Endocrine system > Oxytocin signaling pathway.

· Organismal Systems > Endocrine system > Relaxin signaling pathway.

参考文献

1). Nanostructured organic sheets sequestering small extracellular vesicles and reactive species to protect against radiation-induced mucositis. Nature communications, 2025 (PubMed: 40610425) [IF=16.6]

2). Enhancement of CAR-T cell activity against cholangiocarcinoma by simultaneous knockdown of six inhibitory membrane proteins. Cancer Communications, 2023 (PubMed: 37282786) [IF=16.2]

Application: IHC Species: Human Sample:

FIGURE 1 EGFR‐CAR T cells and B7H3‐CAR T cells exhibited general antitumor activity in cholangiocarcinoma cell lines. (A‐B) Detection of tumor tissue antigens collected from patients with cholangiocarcinoma by IHC staining. The left and right panels of A displayed representative EGFR and B7H3 expression in normal, para‐carcinoma area, and tumor zone with enlarged view (5x, scale bar = 200 μm; 20x, scale bar = 50 μm). Statistical analysis of EGFR and B7H3 antigens scores in normal, para‐carcinoma and carcinoma tissues (B, n = 20). (C) Schematic representation of the lentiviral vectors carrying an EGFR‐specific 3rd generation CAR moiety (EGFR‐CAR) and a B7H3‐specific 3rd generation CAR moiety (B7H3‐CAR). (D) Immunoblotting analysis of EGFR‐CAR and B7H3‐CAR expression were performed with anti‐flag tag. The positive control was GP120‐CAR. (E‐F) Detection cytotoxic activities of the EGFR‐CAR‐T cells and the B7H3‐CAR‐T cells with TFK‐1 cells and HuCCT1 cells by LDH assay. The negative control was Jurkat cells without EGFR and B7H3 expression (n = 3, healthy donors). Experiments were performed independently at least 3 times. One‐way ANOVA was used in Tukey's multiple comparison test. Experimental data are expressed as mean ± SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.001. Abbreviations: CAR, chimeric antigen receptor T; EGFR, epidermal growth factor receptor; B7H3, B7 homolog 3; GP120, gp120 antigen; IHC, immunohistochemistry; LDH, lactate dehydrogenase; SEM, standard error of the mean.

3). Multiomic identification of senescent stem cell populations critical for osteoarthritis progression and therapy in subchondral bones. Science advances, 2025 (PubMed: 40680126) [IF=11.7]

Application: IF/ICC Species: human Sample:

Fig. 3. Spatial transcriptome analysis of the I~II and III~IV side tissues from the patients with OA. (A) the OA signature gene score in the articular surface (AS), super-ficial zone (SZ), middle zone (MZ), and deep zone (dZ) groups. (B) the aging score in the AS, SZ, MZ, and dZ groups. (C) dot plot showing the expression of the senescencegenes in the AS, SZ, MZ, and dZ groups. the size of the dots represents the percentage of genes expressed in the AS, SZ, MZ, and dZ groups. the color of the dot representsthe average expression of the gene. pct.exp, percent expressed. (D) violin plot showing the expression of the representative senescence genes in the AS, SZ, MZ, and dZgroups. (E) Box plot showing the aging score between healthy people and patients with OA in the AS, SZ, MZ, and dZ groups. (F) violin plot showing the expression of theEGFR gene in the AS, SZ, MZ, and dZ groups. (G) Box plot showing the expression of the EGFR gene between healthy people and patients with OA in the AS, SZ, MZ, anddZ groups. (H) Multiplex immunofluorescence staining showing the co-expression of p21, p16, and eGFR in the i~ii and iii~iv side subchondral bone tissues from patientswith OA. dAPi, 4′,6-diamidino- 2- phenylindole. (I) Semiquantitative analysis from five randomly selected low-power fields showing the cell proportion of eGFR+p21+ cellsin each group (n = 5 donors). (J) Semiquantitative analysis from five randomly selected low-power fields showing the cell proportion of eGFR+p16+ cells in each group(n = 5 donors). *P < 0.05; **P < 0.01; ***P < 0.001; n.s., not significant. SB, subchondral bone; StB, subchondral trabecular bone. Ucell, a package for evaluating genesignatures based on the Mann-Whitney U statistic.

4). Bufalin inhibits hepatocellular carcinoma progression by blocking EGFR-mediated RAS-RAF-MEK-ERK pathway activation. Journal of experimental & clinical cancer research : CR, 2025 (PubMed: 40883741) [IF=11.3]

Application: WB Species: human Sample: HepG2 and HCCLM3 cells

Fig. 5 BF inhibits the activation of EGFR-mediated RAS/RAF/MEK/ERK pathway. (A) Immunoblotting of p-EGFR, EGFR, p-RAF, RAF, p-MEK1/2, MEK1/2, p-ERK1/2, ERK1/2, and Pan RAS protein expression in HepG2 and HCCLM3. (B, C) Relative protein expression of p-EGFR/EGFR, p-RAF/RAF, p-MEK1/2/MEK1/2, p-ERK1/2/ERK1/2, and Pan RAS/GAPDH in HepG2 (B) and HCCLM3 (C). (D) IF staining of p-EGFR and p-ERK1/2 in HepG2. (E, F) Relative fluorescence intensity of p-EGFR (E) and p-ERK1/2 (F) in HepG2. Data are expressed as mean ± SD from three independent experiments with biological duplicates. *P

5). Antisense oligonucleotide targeting TARDBP-EGFR splicing axis inhibits progression of oral squamous cell carcinoma through ABCA1-regulated cholesterol efflux. International journal of oral science, 2026 (PubMed: 41540015) [IF=10.8]

6). Foxq1 promotes metastasis of nasopharyngeal carcinoma by inducing vasculogenic mimicry via the EGFR signaling pathway. Cell Death & Disease, 2021 (PubMed: 33875643) [IF=8.1]

Application: WB Species: mouse Sample: 5–8F cells and CNE1

Fig. 3| Foxq1 increases the expression of EGFR, while Erlotinib inhibits Foxq1-induced VM formation. A, B qRT-PCR was used to assess the expression of predicted genes in 5–8F cells that overexpressed miR-124 or had a Foxq1 knockdown. C–F qRT-PCR (left) and western blot (right) of EGFR expression in Foxq1 dysregulated 5–8F, and CNE1.

Application: IHC Species: mouse Sample: NPC tissues

Application: IF/ICC Species: mouse Sample: 5–8F cells

Fig. 7| MiR-124 inhibits the EGFR signaling pathway and VM formation, that could be rescued by Foxq1 expression. E Immunofluorescence staining of Foxq1, EGFR, VE-cadherin, MMP2 and MMP9 in 5–8F cells that overexpressed miR-124, control or simultaneously Foxq1 and miR-124, respectively; scale bars represent 50μm. qRT-PCR (F) and western blot (G) were used to monitor the expression of EGFR signaling pathway and VM-related genes in 5–8F cells that overexpressed miR-124, control or simultaneously Foxq1 and miR-124, respectively.Data are presented as mean ± SD of three independent experiments.

7). CircEGFR reduces the sensitivity of pirarubicin and regulates the malignant progression of triple-negative breast cancer via the miR-1299/EGFR axis. International journal of biological macromolecules, 2023 (PubMed: 37302631) [IF=7.7]

8). Higenamine alleviates allergic rhinitis by activating AKT1 and suppressing the EGFR/JAK2/c-JUN signaling. PHYTOMEDICINE, 2021 (PubMed: 33945919) [IF=6.7]

Application: WB Species: Human Sample: HNEpCs

Fig. 8. The effects of higenamine (HG) on potential targets in histamine-induced HNEpCs. (A-J) Levels of protein expression of AKT1, p-AKT1, EGFR, p-EGFR, c-Jun, p-c-Jun, iNOS, JAK2, and p-JAK2 were determined by Western blotting, β-actin was used as an internal control. Data are expressed as means ± SD of three experiments. ## p < 0.01, and # p < 0.05 compared with the control group. ** p < 0.01, and * p < 0.05 compared with the histamine group.

9). Multi-omics analyses reveal that hesperidin ameliorates high-altitude pulmonary hypertension by restoring gut-lung axis homeostasis. Phytomedicine : international journal of phytotherapy and phytopharmacology, 2025 (PubMed: 40680331) [IF=6.7]

Application: WB Species: Rat Sample:

Fig. 9. Details of DEMs and DEGs enriched in the ‘choline metabolism in cancer pathway’ (n = 6 per group). (A) DEMs among groups. (B) Serum levels of choline, total lysophosphatidylcholine, glycerophosphocholine, and TMAO measured by ELISA. (C) DEGs among groups. (D) Western blot bands of EGFR, c-Fos, and WASF1 in rat pulmonary tissues. (E) Quantitative results of EGFR, c-Fos, and WASF1 expression. ns, non-significance (p > 0.05).

10). Resistance to anti-HER2 therapy associated with the TSC2 nonsynonymous variant c.4349 C > G (p.Pro1450Arg) is reversed by CDK4/6 inhibitor in HER2-positive breast cancer. npj Breast Cancer, 2023 (PubMed: 37160904) [IF=5.9]

Application: WB Species: Human Sample: BT474 cell

Fig. 3 Expression of proteins involved in the HER2/AKT/mTOR and cyclinD1/CDK4 signaling pathways in BT474 cell lines treated with lapatinib and/or palbociclib. a Western blot analysis of proteins involved in the HER2/AKT/mTOR signaling pathway after treatment with lapatinib and/or palbociclib for 48 h. b Western blot analysis of proteins involved in the cyclinD1/CDK4 signaling pathway after treatment with lapatinib and/or palbociclib for 48 h. c p-HER2 expression levels under treatment with different drugs in the same cell. d p-HER2 expression levels in TSC2-NC, WT, and MT groups treated with the same drugs. e p-TSC2 expression levels under treatment with different drugs in the same cell. f p-TSC2 expression levels in TSC2-NC, WT, and MT groups treated with the same drugs. g p-mTOR expression levels under treatment with different drugs in the same cell. h p-mTOR expression levels in TSC2-NC, WT, and MT groups treated with the same drugs. i p-P70S6K expression levels under treatment with different drugs in the same cell. j p-P70S6K expression levels in TSC2-NC, WT, and MT groups treated with the same drugs. Data are shown as mean ± SD; One-way ANOVA was used to analyze the data in (d, f, h, j). Error bars are SEM.

Restrictive clause

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.

EGFR Antibody - #AF6043

関連製品情報

関連ダウンロード

MSDS

説明書

COA